Propanc Biopharma Inc’s Lock-Up Period Will Expire on February 11th (OTCMKTS:PPCB)

Propanc Biopharma’s (OTCMKTS:PPCB) lock-up period will end on Wednesday, February 11th. Propanc Biopharma had issued 1,000,000 shares in its initial public offering on August 15th. The total size of the offering was $4,000,000 based on an initial share price of $4.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the expiration of the lock-up period.

Propanc Biopharma Stock Performance

Shares of PPCB opened at $0.22 on Wednesday. The stock has a market capitalization of $2.94 million, a PE ratio of 0.00 and a beta of 3.45. The business’s fifty day moving average price is $0.57 and its 200 day moving average price is $2.14. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.24 and a quick ratio of 2.24. Propanc Biopharma has a 12-month low of $0.20 and a 12-month high of $11.00.

Hedge Funds Weigh In On Propanc Biopharma

A hedge fund recently bought a new stake in Propanc Biopharma stock. Virtu Financial LLC bought a new stake in shares of Propanc Biopharma Inc (OTCMKTS:PPCB) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 41,677 shares of the company’s stock, valued at approximately $71,000. Virtu Financial LLC owned about 0.33% of Propanc Biopharma at the end of the most recent quarter.

Propanc Biopharma Company Profile

Propanc Biopharma Ltd is a clinical-stage biotechnology company focused on developing novel biologic drug candidates for the treatment of invasive and metastatic cancers. The company’s core technology centers on proprietary formulations of recombinant human proteolytic enzymes designed to degrade the dense extracellular matrix that surrounds solid tumors. By reducing stromal barriers, these candidates are intended to enhance the delivery and efficacy of co-administered chemotherapies, immunotherapies or other targeted agents.

The company’s lead program, known as PRP, comprises a combination of modified pancreatic proteases that have demonstrated promising preclinical activity in degrading tumor stroma and inhibiting tumor growth.